X
[{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spago Nanomedical Appoints Candidate Drug in the Tumorad Project","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spago Nanomedical Initiates Clinical Trial with SpagoPix in Endometriosis and Concludes SPAGOPIX-01","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"IND Enabling","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spago Nanomedical has Submitted Application to Start Tumorad(R) Clinical Phase I\/IIa Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spago Nanomedical Receives Approval to Initiate the Clinical Phase I\/IIa study with Tumorad(R) in Australia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spago Nanomedical Proceeds to the Next Dose Level in the Phase I\/IIa Study Tumorad-01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Spago Nanomedical's Clinical Phase I\/IIa Study within the Tumorad(R) Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spago Nanomedical Reports Favorable Data in Breast Cancer Model with Tumorad","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spago Nanomedical Provides an Update on Tumorad-01 - Trial Proceeds as Planned","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Spago Nanomedical
Filters
Companies By Therapeutic Area
Details:
Tumorad (177Lu-SN201) is a ionisisng radiation emmiter which is under phase 1/2 clinical development for the treatment of advanced cancer,
Lead Product(s):
177Lu-SN201
Therapeutic Area: Oncology
Product Name: Tumorad
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 20, 2024
Details:
Tumorad (177Lu]Lu-SN201) is a ionisisng radiation emmiter, which is being evaluated for the treatment of 4T1 orthotopic triple-negative breast cancer.
Lead Product(s):
177Lu-SN201
Therapeutic Area: Oncology
Product Name: Tumorad
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 24, 2024
Details:
Tumorad (177Lu]Lu-SN201) is a ionisisng radiation emmiter which is under phase 1/2 clinical development for the treatment of advanced cancer,
Lead Product(s):
[177Lu]Lu-SN201
Therapeutic Area: Oncology
Product Name: Tumorad
Highest Development Status: Phase I/ Phase II
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 10, 2024
Details:
The investigational drug candidate from Sapgo, 177Lu-SN201, a radio-labeled compound, is currently undergoing evaluation in Phase I/II clinical trial studies with patients for treating advanced solid tumors.
Lead Product(s):
177Lu-SN201
Therapeutic Area: Oncology
Product Name: 177Lu-SN201
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 07, 2023
Details:
177Lu-SN201 has been optimally designed for physiological targeting by means of the EPR effect. Preclinical results from different tumor models confirm accumulations in tumors, inhibited tumor growth and extended survival.
Lead Product(s):
177Lu-SN201
Therapeutic Area: Oncology
Product Name: 177Lu-SN201
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 19, 2023
Details:
177Lu-SN201 is clinically effective against cancer. Combined with Spago Nanomedical´s carefully designed polymeric nanomaterial, the candidate promising new radionuclide therapy for physiological targeting and tumor selective treatment of cancer.
Lead Product(s):
177Lu-SN201
Therapeutic Area: Oncology
Product Name: 177Lu-SN201
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 23, 2023
Details:
The study will evaluate the safety and MRI enhancing properties of SN132D in participants with suspected endometriosis. Comparisons will be made to transvaginal ultrasound and conventional MRI in order to consider the diagnostic potential of SN132D in endometriosis.
Lead Product(s):
SN132D
Therapeutic Area: Obstetrics/Gynecology (Women’s Health)
Product Name: SN132D
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 05, 2022
Details:
In a mouse model for breast cancer, Spago has shown that Tumorad® significantly reduces tumor growth and prolongs survival. Based on this and previously communicated progress in the project, Spago has nominated Tumorad® or SN201 for Pre-clinical safety tests.
Lead Product(s):
Tumorad-Lu177
Therapeutic Area: Oncology
Product Name: SN201
Highest Development Status: Preclinical
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 24, 2020